

FIG. 1





FIG. 2






FIG. 3





FIG. 4

23.1-
2.0-
0.56-
Kb

M 1 2 3 4 5 6 7 8 9 10 11



CML CLL

CML cells:
1, Control
2, ara-C, 1 μ M
3, 2-ME, 10 μ M

CLL cells:
4, Control
5, 2-ME, 10 μ M
6, 2-ME, 30 μ M
7, F-ara-A, 1 μ M
8, F-ara-A, 3 μ M
9, F-ara-A, 10 μ M
10, M 10 + F1
11, M 10 + F3

FIG. 5




FIG. 6




FIG. 7





FIG. 8







FIG. 10

FIG. 11

Control ML-1 cells

2-ME, 1 μ M, 5 h



Time (h): 0 2 4 6 10

SOD, ML-1

SOD, HL-60

FIG. 12




FIG. 13




FIG. 14




FIG. 15








FIG. 16

FIG. 17A**FIG. 17B****FIG. 17C****FIG. 17D**

e

Survival (% control) of cells treated with 2-ME.

	2-ME, μM	
	10	30
Normal	96 ± 11	88 ± 15
CLL	72 ± 26	33 ± 19
p value	0.0109	<0.0001

FIG. 17E



FIG. 18A**FIG. 18C****FIG. 18B****FIG. 18D**

FIG. 19A




FIG. 19B






FIG. 19C

FIG. 19D








FIG. 20

FIG. 21A**FIG. 21D****FIG. 21B****FIG. 21E****FIG. 21C**Colony formation (% control)
in H1299 cells

2-ME (μM)	Vector		
	Ad-cont.	SOD1	SOD2
0	100	100	100
0.03	70	105	100
0.1	84	98	83
0.3	43	69	51
0.5	15	39	32
1.0	0	5	0


FIG. 21F

FIG. 22A





FIG. 22B




FIG. 23





FIG. 24

Cellular superoxide

卷之三

Rot.: - .05 .1 .25 .5 1 5 - .05 .25 - .05 .25 (μ M)

2-ME: - - - - - - - - - - .3 .3 .3 (μ M)



20

4

FIG. 25




FIG. 26




FIG. 27

Rot.	Drug, nM	Cellular NTP, μM			
		ATP	CTP	UTP	GTP
-	-	761 \pm 61	65 \pm 6	174 \pm 3	160 \pm 10
50	-	651 \pm 8	50 \pm 3	146 \pm 8	128 \pm 4
-	300	711 \pm 15	76 \pm 4	181 \pm 16	159 \pm 1
50	300	506 \pm 2	53 \pm 1	117 \pm 10	112 \pm 3

FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43